BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 3, 2026 /CNW/ - Principal Technologies Inc. (TSXV: PTEC) (FWB:...
Archaeological Impact Assessment complete – no issues identifiedSummer drill program and rock mechanics analysis planned to support Pre-Feasibility StudyActive engagement with First Nations and...
Issued on behalf of General Fusion Inc.VANCOUVER, BC, June 3, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary — Fusion has been "thirty years away" for...
Issued on behalf of General Fusion Inc.VANCOUVER, BC, June 3, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Fusion has been "thirty years away" for...
HIGHLIGHTSUS$346,457,132 of Existing Notes, or 97.88% of all Existing Notes, have been tenderedThe Companies have met the Minimum Participation Condition and the Clean-Up Call...